Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MIF | P14174 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CD74 | P04233 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | RGS4 | P49798 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31667303 | 0.86 | POLB (0.42) | KMT2AMIFALDH1A1SMN1; SMN2CD74 | |
| SCHEMBL31667438 | 0.79 | MIF (0.71) | KMT2AMIFALDH1A1SMN1; SMN2CD74 | |
| SCHEMBL20725151 | 0.76 | MIF (0.76) | KMT2AMIFALDH1A1SMN1; SMN2CD74 | |
| SCHEMBL31667394 | 0.75 | MAPT (0.42) | KMT2ASMN1; SMN2MAPTKDM4EPOLB | |
| SCHEMBL18805695 | 0.75 | IDO1 (0.72) | KMT2AMIFALDH1A1SMN1; SMN2CD74 | |
| SCHEMBL16099478 | 0.72 | POLB (0.51) | KMT2AMIFALDH1A1CD74MAPT | |
| SCHEMBL32674374 | 0.71 | KMO (0.45) | KMT2AMIFALDH1A1CD74LMNA | |
| SCHEMBL32674486 | 0.71 | ALDH1A1 (0.41) | KMT2AMIFALDH1A1CD74MAPT | |
| SCHEMBL32674120 | 0.71 | MIF (0.41) | KMT2AMIFALDH1A1SMN1; SMN2CD74 | |
| SCHEMBL18805706 | 0.70 | MIF (0.62) | KMT2AMIFALDH1A1CD74MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | KMT2A 2737/4885MIF 4403/4885ALDH1A1 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.